Dark Blue Therapeutics
Amgen Acquires Oxford Spinout Dark Blue Therapeutics for Up to $840 Million, Gaining Preclinical Cancer Drug
Amgen; Dark Blue Therapeutics; acquisition; Oxford spinout; DBT 3757; AML; ALL; protein degrader
Actionable Insights Powered by AI
Amgen; Dark Blue Therapeutics; acquisition; Oxford spinout; DBT 3757; AML; ALL; protein degrader